FDA Grants First-Ever Approval for Cerebral Venous Stent to Treat Severe Idiopathic Intracranial Hypertension
核心洞察
The FDA has granted Serenity Medical (搜索)'s River stent (搜索) a humanitarian device exemption, marking the first cerebral venous stent approved for treating severe idiopathic intracranial hypertension (搜索) (IIH (搜索)).
The approval is based on the River Study, a 39-patient multicenter trial that demonstrated a 5.4% major adverse event rate at one year and improvements in cerebrospinal fluid pressure (搜索), headaches, and quality of life scores.
The stent is indicated for adult IIH (搜索) patients with significant stenosis who have failed medical therapy for six months or more, addressing a critical unmet need in this underserved patient population.
The US Food and Drug Administration (搜索) has granted Serenity Medical (搜索)'s River stent (搜索) a humanitarian device exemption (HDE), making it the first cerebral venous stent approved for treating severe idiopathic intracranial hypertension (搜索) (IIH (搜索)). This landmark regulatory milestone addresses a critical unmet medical need for patients with a debilitating neurological condition that has historically lacked FDA-approved surgical treatment options.
Addressing a Critical Medical Need
IIH (搜索) is a serious neurological condition caused by elevated intracranial pressure, leading to debilitating chronic headaches (搜索), vision loss (搜索), and cognitive impairment (搜索). The condition disproportionately affects women aged 20-50 with obesity, a demographic growing in prevalence. For patients with severe IIH symptoms, finding appropriate surgical therapies that are FDA-approved and indicated to safely relieve symptoms has been particularly challenging.
"Delivering the first venous stent approved for severe, refractory IIH (搜索) is incredibly meaningful to our dedicated team and to people living with IIH who have had limited options for relief until now," said Y. Pierre Gobin, MD, Founder of Serenity Medical (搜索) and an internationally recognized neurointerventional expert practicing at Weill-Cornell Medicine (搜索) in New York.
Clinical Evidence Supporting Approval
The FDA's approval is based on findings from the River Study, the first multicenter trial of a novel venous stent for IIH (搜索) treatment, published in the Journal of Neurointerventional Surgery in February 2025. The prospective, open-label, multi-center, single-arm trial enrolled 39 subjects at five US centers and aimed to demonstrate the safety and probable benefit of the River stent (搜索) in patients who are refractory or intolerant to medications.
At one year, the River stent (搜索) met the study's primary safety endpoint, with an observed major adverse event rate of 5.4%. The trial demonstrated improvements across multiple clinical parameters, including opening cerebrospinal fluid pressure (搜索), headaches, papilledema (搜索), pulsatile tinnitus (搜索), visual symptoms, and patients' Quality of Life scores.
"The River Study was groundbreaking as the first-of-its-kind study to evaluate a stent specifically designed for intracranial venous sinuses (搜索)," said Adnan Siddiqui, MD, PhD, vice chairman and professor of neurosurgery at Jacobs School of Medicine & Biomedical Sciences (搜索), and senior author on the study. "There is no other stent that is optimized or approved for this indication."
Device Design and Indication
The River stent (搜索) is specifically designed to hold open narrowed veins in the brain to improve blood drainage and reduce pressure, thereby alleviating IIH (搜索) symptoms. Under the HDE approval, the stent is indicated for adult patients with IIH with significant stenosis who are resistant or intolerant to medications.
The device is reserved for patients with severe headaches who have failed to respond to six months or more of medical therapy, including attempted weight loss, or for patients who have had visual symptoms or visual signs that are vision-threatening despite medical therapy.
Commercial Strategy and Market Access
Serenity Medical (搜索) has formed a strategic partnership with Radical Catheter Technologies (搜索) to commercialize the River stent (搜索). The collaboration aims to accelerate access for indicated patients through specialized neurovascular expertise and proven commercialization capabilities.
"The FDA's review and acceptance of these data will now enable access to this important tool to the broader medical community to treat these patients," noted Siddiqui, emphasizing the significance of having a purpose-built, FDA-approved device for this challenging condition.
The approval represents years of persistence and partnership with investigators, reflecting a shared commitment to bring new treatment possibilities to an underserved patient community that has long challenged the neurovascular medical community.